Related Experiment Video
Updated: Jul 15, 2025

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
Mechanisms of kidney fibrosis and routes towards therapy
Noriyuki Yamashita1, Rafael Kramann2
1Department of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany; Department of Nephrology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Abstract:
Kidney fibrosis is the final common pathway of virtually all chronic kidney diseases (CKDs) and is therefore considered to be a promising therapeutic target for these conditions. However, despite great progress in recent years, no targeted antifibrotic therapies for the kidney have been approved, likely because the complex mechanisms that initiate and drive fibrosis are not yet completely understood. Recent single-cell genomic approaches have allowed novel insights into kidney fibrosis mechanisms in mouse and human, particularly the heterogeneity and differentiation processes of myofibroblasts, the role of injured epithelial cells and immune cells, and their crosstalk mechanisms. In this review we summarize the key mechanisms that drive kidney fibrosis, including recent advances in understanding the mechanisms, as well as potential routes for developing novel targeted antifibrotic therapeutics.
Insights
Kidney fibrosis, a common pathway in chronic kidney diseases (CKDs), remains poorly understood. Recent single-cell genomics reveal complex cellular interactions driving fibrosis, offering new therapeutic targets.
Area of Science:
- Nephrology
- Genomics
- Cell Biology
Background:
- Kidney fibrosis is a common endpoint for chronic kidney diseases (CKDs).
- Current understanding of fibrosis mechanisms is incomplete, hindering antifibrotic therapy development.
- No targeted antifibrotic therapies for the kidney have been approved.
Purpose of the Study:
- To review key mechanisms driving kidney fibrosis.
- To highlight recent advances in understanding fibrosis initiation and progression.
- To explore potential routes for novel targeted antifibrotic therapeutics.
Main Methods:
- Review of recent single-cell genomic studies in mouse and human models.
- Analysis of cellular heterogeneity and differentiation processes.
- Examination of crosstalk mechanisms between kidney cells.
Main Results:
- Single-cell genomics provide novel insights into kidney fibrosis.
- Identified heterogeneity and differentiation of myofibroblasts.
- Elucidated roles of injured epithelial and immune cells and their crosstalk.
Conclusions:
- Understanding complex cellular crosstalk is crucial for kidney fibrosis.
- Targeted antifibrotic therapies may emerge from insights into cellular mechanisms.
- Further research into myofibroblast, epithelial, and immune cell interactions is warranted.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction

